Medical Condition News

RSS

Obese type 2 diabetics carry mitochondrial proteins that reduce response to physical exercise

Diet and aerobic exercise are highly effective for the treatment of type 2 diabetes, but not for obese subjects that have developed the disease when very young. A study at the Institute for Research in Biomedicine and Trinity College in Dublin demonstrates that obese subjects between 18 and 25 years of age carry mitochondrial proteins and genes that work abnormally and that these anomalies contribute to generating insulin resistance and a reduced response to physical exercise.

15 Mar 2010

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Ligand Pharmaceuticals Incorporated today announced that GlaxoSmithKline was granted marketing authorization from the European Commission for Revolade® (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

15 Mar 2010

New study finds green tea extract may prevent Alzheimer's disease and dementia

Long known to be beneficial in heart disease, diabetes and some cancers, a new study finds a specific green tea extract may delay or prevent Alzheimer's disease and dementia. A. Holliday & Company's "Teawell 50," is a 50 percent pure extraction of EGCG (epigallocatechin gallate) – a flavonoid which is the most potent of four major catechins in green tea.

15 Mar 2010

Discovery of MiR-451 molecule may serve as a biomarker for brain tumor

Cancer cells in rapidly growing brain tumors must adjust to periods of low energy or die. When energy levels are high, tumor cells grow and proliferate. When levels are low, the cells grow less and migrate more.

15 Mar 2010

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Bio-Path Holdings, Inc., a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today that the U.S. Food and Drug Administration has allowed an IND (Investigational New Drug) for the Company’s lead cancer drug candidate liposomal Grb-2 to proceed into clinical trials.

15 Mar 2010

Brain Science Institute, Eisai sign licensing agreement to develop GCPII inhibitors

Johns Hopkins University's newly formed Brain Science Institute's NeuroTranslational Program has entered into a licensing agreement with pharmaceutical company Eisai Inc. to discover and develop small molecule glutamate carboxypeptidase II (GCPII) inhibitors.

15 Mar 2010

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

Cardiovascular risk can be reduced by an additional 31 percent in type 2 diabetes patients with atherogenic dyslipidemia, the common combination of elevated triglycerides (TG, 204 mg/dL or 2.3 mmol/L or higher) and low levels of high-density lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L or lower).

15 Mar 2010

Prioritizing end of life care for cancer patients

Despite the advances and groundbreaking research being performed in the area of cancer treatment, sometimes cancer cannot be cured. In this situation, patients and their families are faced with complex emotions and a variety of end of life issues and decisions.

15 Mar 2010

Telemonitoring may reduce mortality of heart failure patients by 20%

Telemonitoring may reduce the mortality of patients with heart failure by 20%. Silke Schmidt et al. present their study results in the current issue of Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[8]131-8).

12 Mar 2010

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.

12 Mar 2010

Experts: Americans get too many tests, too much treatment

"Too much cancer screening, too many heart tests, too many cesarean sections. A spate of recent reports suggest that too many Americans -- maybe even President Barack Obama -- are being overtreated." Defensive medicine and a culture focusing on medical technology have lead to overtesting but "now new evidence and guidelines are recommending a step back and more thorough doctor-patient conversations about risks and benefits."

12 Mar 2010

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability.

12 Mar 2010

Antibiotics lower risk of developing gastric cancer

Helicobacter pylori, a bacterium found in about 50% of humans worldwide, can cause stomach ulcers and, in extreme cases, gastric cancer. In an article for F1000 Medicine Reports, Seiji Shiota and Yoshio Yamaoka discuss the possible eradication of H. pylori infections

12 Mar 2010

St. Jude Medical to exhibit cardiac clinical solution products portfolio at ACC 2010

St. Jude Medical, Inc. today announced it will display products and technologies from the company’s wide array of clinical solutions in the cardiology, cardiac surgery, atrial fibrillation and cardiac rhythm management markets at ACC 2010.

12 Mar 2010

$Bisphosphonate treatments may affect bone quality and increase risk of atypical fractures of femur$

Bisphosphonate treatments may affect bone quality and increase risk of atypical fractures of femur

Bisphosphonate treatments, proven to enhance bone density and reduce fracture incidence in post-menopausal women, may adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years, according to preliminary research presented today at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons.

12 Mar 2010

Vertos Medical announces positive results from IRB I Patient Outcomes Trial of 'mild' for LSS

Medical device company Vertos Medical Inc. has announced the release of positive results from its U.S. IRB I Patient Outcomes Trial, a prospective, investigational review board-approved, 75-patient study of mild for the treatment of lumbar spinal stenosis (LSS). Six-week clinical data have shown that patients treated with mild experience statistically and clinically significant improvement in both pain and functional ability. The data also confirmed mild’s safety, with no reports of patient complications related to the procedure or the devices.

12 Mar 2010

Vermont: Only state to pass bill mandating coverage of colon cancer screening

Progress towards nationwide, state-mandated coverage of colon cancer screening according to accepted medical guidelines has slowed to a crawl as state legislators await the outcome of the health care reform debate at the federal level, a coalition of public health associations and medical professional societies reported today. With a better grade for only a single state – Vermont – 2009 marks the least improvement in a single year since the Colorectal Cancer Legislation Report Card began in 2004.

12 Mar 2010

CoreObjects receives PMI Excellence Award for developing HbA1c Blood Sugar Analysis device

CoreObjects is proud to announce the achievement of the Project Management Institutes "Excellence Award" for their role in helping launch a product that enhances the quality of life for patients suffering from diabetes.

12 Mar 2010

University of Tennessee CST effectively detects cognitive abnormalities associated with Alzheimer's disease

Early detection is key to more effective treatment for Alzheimer's disease and other forms of cognitive impairment, and new research shows that a test developed at the University of Tennessee is more than 95 percent effective in detecting cognitive abnormalities associated with these diseases.

12 Mar 2010

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) -- including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees -- discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT® (budesonide/formoterol fumarate dihydrate).

12 Mar 2010

Medical Condition News

Obese type 2 diabetics carry mitochondrial proteins that reduce response to physical exercise

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

New study finds green tea extract may prevent Alzheimer's disease and dementia

Discovery of MiR-451 molecule may serve as a biomarker for brain tumor

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Brain Science Institute, Eisai sign licensing agreement to develop GCPII inhibitors

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

Prioritizing end of life care for cancer patients

Telemonitoring may reduce mortality of heart failure patients by 20%

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

Experts: Americans get too many tests, too much treatment

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

Antibiotics lower risk of developing gastric cancer

St. Jude Medical to exhibit cardiac clinical solution products portfolio at ACC 2010

Bisphosphonate treatments may affect bone quality and increase risk of atypical fractures of femur

Vertos Medical announces positive results from IRB I Patient Outcomes Trial of 'mild' for LSS

Vermont: Only state to pass bill mandating coverage of colon cancer screening

CoreObjects receives PMI Excellence Award for developing HbA1c Blood Sugar Analysis device

University of Tennessee CST effectively detects cognitive abnormalities associated with Alzheimer's disease

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News